Close Menu

stock rating

NEW YORK (GenomeWeb News) – Following a spike in Life Technologies' share price after a report that the company may be searching for a buyer.

NEW YORK (GenomeWeb News) – Mizuho Securities analyst Peter Lawson today downgraded the stock of Becton Dickinson from Buy to Neutral.

NEW YORK (GenomeWeb News) – Goldman Sachs today resumed coverage of Danaher with a Neutral rating and a 12-month price target of $57.

NEW YORK (GenomeWeb News) – Investment bank Robert W. Baird has downgraded Illumina's stock to Neutral, citing "near-term obstacles."

NEW YORK (GenomeWeb News) – Goldman Sachs has upgraded the stock of Agilent Technologies and Bruker, but downgraded Cepheid and Laboratory Corporation of America.

NEW YORK (GenomeWeb News) – Investment bank Jefferies today upgraded shares of Sequenom to Buy following a survey of US commercial payors that suggests the San Diego-based firm is gaining "meaningful traction" in getting coverage for its MaterniT21 Plus LDT test.

NEW YORK (GenomeWeb News) – Goldman Sachs today initiated coverage of Genomic Health with a Neutral rating and a six-month price target on its stock of $36.

NEW YORK (GenomeWeb News) – Mizuho Securities today downgraded Fluidigm to Neutral, citing a cooling sentiment to both the genomics and academic markets.

NEW YORK (GenomeWeb News) – Piper Jaffray on Thursday initiated coverage of diagnostics firm Quidel with an Overweight rating, noting the San Diego-based company's move into the molecular diagnostics space.
The investment bank has a $26 price target on Quidel's stock.

NEW YORK (GenomeWeb News) – In a nod to the growing influence of diagnostic products and services on clinical decisions, investment bank Cowen & Co. today initiated coverage of several firms operating in the molecular diagnostics and 'omics-related life science spaces.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.